State Street Corp Acquires 45,483 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

State Street Corp grew its holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 1.8% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 2,608,352 shares of the company’s stock after acquiring an additional 45,483 shares during the period. State Street Corp’s holdings in Lineage Cell Therapeutics were worth $2,361,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in LCTX. Raffles Associates LP raised its holdings in Lineage Cell Therapeutics by 35.8% in the 2nd quarter. Raffles Associates LP now owns 4,357,781 shares of the company’s stock valued at $4,346,000 after acquiring an additional 1,147,800 shares during the period. Bank of New York Mellon Corp grew its position in shares of Lineage Cell Therapeutics by 35.7% in the second quarter. Bank of New York Mellon Corp now owns 435,958 shares of the company’s stock valued at $435,000 after purchasing an additional 114,762 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Lineage Cell Therapeutics during the third quarter worth approximately $84,000. XTX Topco Ltd acquired a new stake in Lineage Cell Therapeutics during the 2nd quarter worth approximately $61,000. Finally, Renaissance Technologies LLC boosted its stake in Lineage Cell Therapeutics by 10.0% in the 2nd quarter. Renaissance Technologies LLC now owns 583,622 shares of the company’s stock valued at $582,000 after purchasing an additional 53,022 shares during the period. 62.47% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on LCTX. HC Wainwright increased their price objective on Lineage Cell Therapeutics from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. D. Boral Capital lowered their price target on shares of Lineage Cell Therapeutics from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th.

Lineage Cell Therapeutics Stock Performance

Shares of NYSEAMERICAN:LCTX opened at $0.50 on Wednesday. Lineage Cell Therapeutics, Inc. has a 1 year low of $0.48 and a 1 year high of $1.61. The company has a market cap of $110.76 million, a P/E ratio of -4.19 and a beta of 1.16.

Lineage Cell Therapeutics Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.